Larchwood Care

larchwoodcare.co.uk

Larchwood Care is proud to offer exceptional standards of respite and residential care in our 58 Care Homes across Scotland, England and Wales. We are committed to providing the very best care in a safe and comfortable environment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

TEXAS CHILDREN'S PAVILION FOR WOMEN ACQUIRES AUSTIN PERINATAL ASSOCIATES EXPANDING HOSPITAL'S MATERNAL-FETAL MEDICINE FOOTPRINT TO CENTRAL TEX

Texas Children's Hospital | May 09, 2022

news image

Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin. Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...

Read More

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

news image

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More

MEDICAL

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More

CELL AND GENE THERAPY

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

news image

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More
news image

MEDICAL

TEXAS CHILDREN'S PAVILION FOR WOMEN ACQUIRES AUSTIN PERINATAL ASSOCIATES EXPANDING HOSPITAL'S MATERNAL-FETAL MEDICINE FOOTPRINT TO CENTRAL TEX

Texas Children's Hospital | May 09, 2022

Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin. Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...

Read More
news image

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More
news image

MEDICAL

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More
news image

CELL AND GENE THERAPY

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More